These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 35643116)

  • 1. Development and Internal Validation of a Prognostic Model of the Probability of Death or Lung Transplantation Within 2 Years for Patients With Cystic Fibrosis and FEV
    Ramos KJ; Hee Wai T; Stephenson AL; Sykes J; Stanojevic S; Rodriguez PJ; Bansal A; Mayer-Hamblett N; Goss CH; Kapnadak SG
    Chest; 2022 Oct; 162(4):757-767. PubMed ID: 35643116
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Heterogeneity in Survival in Adult Patients With Cystic Fibrosis With FEV
    Ramos KJ; Quon BS; Heltshe SL; Mayer-Hamblett N; Lease ED; Aitken ML; Weiss NS; Goss CH
    Chest; 2017 Jun; 151(6):1320-1328. PubMed ID: 28115168
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Skilton M; Krishan A; Patel S; Sinha IP; Southern KW
    Cochrane Database Syst Rev; 2019 Jan; 1(1):CD009841. PubMed ID: 30616300
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival and Lung Transplant Outcomes for Individuals With Advanced Cystic Fibrosis Lung Disease Living in the United States and Canada: An Analysis of National Registries.
    Ramos KJ; Sykes J; Stanojevic S; Ma X; Ostrenga JS; Fink A; Quon BS; Marshall BC; Faro A; Petren K; Elbert A; Goss CH; Stephenson AL
    Chest; 2021 Sep; 160(3):843-853. PubMed ID: 33878343
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ivacaftor for the treatment of patients with cystic fibrosis and the G551D mutation: a systematic review and cost-effectiveness analysis.
    Whiting P; Al M; Burgers L; Westwood M; Ryder S; Hoogendoorn M; Armstrong N; Allen A; Severens H; Kleijnen J
    Health Technol Assess; 2014 Mar; 18(18):1-106. PubMed ID: 24656117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiopulmonary Exercise Testing Provides Prognostic Information in Advanced Cystic Fibrosis Lung Disease.
    Radtke T; Urquhart DS; Braun J; Barry PJ; Waller I; Petch N; Mei-Zahav M; Kramer MR; Hua-Huy T; Dinh-Xuan AT; Innes JA; McArthur S; Sovtic A; Gojsina B; Verges S; de Maat T; Morrison L; Wood J; Crute S; Williams CA; Tomlinson OW; Bar-Yoseph R; Hebestreit A; Quon BS; Kwong E; Saynor ZL; Causer AJ; Stephenson AL; Schneiderman JE; Shaw M; Dwyer T; Stevens D; Remus N; Douvry B; Foster K; Benden C; Ratjen F; Hebestreit H;
    Ann Am Thorac Soc; 2024 Mar; 21(3):411-420. PubMed ID: 37879036
    [No Abstract]   [Full Text] [Related]  

  • 7. Validation of the French 3-year prognostic score for death or lung transplant in the United States cystic fibrosis population.
    Ramos KJ; Wai TH; Sykes J; Ma X; Stephenson AL; Jennerich AL; Kapnadak SG; Mayer-Hamblett N; Goss CH
    J Cyst Fibros; 2022 May; 21(3):471-474. PubMed ID: 34465539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Longitudinal Trends in Real-World Outcomes after Initiation of Ivacaftor. A Cohort Study from the Cystic Fibrosis Registry of Ireland.
    Kirwan L; Fletcher G; Harrington M; Jeleniewska P; Zhou S; Casserly B; Gallagher CG; Greally P; Gunaratnam C; Herzig M; Linnane B; McElvaney NG; McKone EF; McNally P; Mullane D; Ní Chróinín M; O'Mahony M; Plant BJ; Jackson AD
    Ann Am Thorac Soc; 2019 Feb; 16(2):209-216. PubMed ID: 30427731
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sustained Benefit from ivacaftor demonstrated by combining clinical trial and cystic fibrosis patient registry data.
    Sawicki GS; McKone EF; Pasta DJ; Millar SJ; Wagener JS; Johnson CA; Konstan MW
    Am J Respir Crit Care Med; 2015 Oct; 192(7):836-42. PubMed ID: 26132840
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mortality Risk and Pulmonary Function in Adults With Cystic Fibrosis at Time of Wait Listing for Lung Transplantation.
    Hayes D; Kirkby S; Whitson BA; Black SM; Sheikh SI; Tobias JD; Mansour HM; Kopp BT
    Ann Thorac Surg; 2015 Aug; 100(2):474-9. PubMed ID: 26138770
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
    Patel S; Sinha IP; Dwan K; Echevarria C; Schechter M; Southern KW
    Cochrane Database Syst Rev; 2015 Mar; (3):CD009841. PubMed ID: 25811419
    [TBL] [Abstract][Full Text] [Related]  

  • 12. First experience in Switzerland in Phe508del homozygous cystic fibrosis patients with end-stage pulmonary disease enrolled in a lumacaftor-ivacaftor therapy trial - preliminary results.
    Murer C; Huber LC; Kurowski T; Hirt A; Robinson CA; Bürgi U; Benden C
    Swiss Med Wkly; 2018; 148():w14593. PubMed ID: 29451946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pulmonary Artery Pressure and Benefit of Lung Transplantation in Adult Cystic Fibrosis Patients.
    Hayes D; Tumin D; Daniels CJ; McCoy KS; Mansour HM; Tobias JD; Kirkby SE
    Ann Thorac Surg; 2016 Mar; 101(3):1104-9. PubMed ID: 26687141
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Impact of pulmonary hypertension on survival in patients with cystic fibrosis undergoing lung transplantation: an analysis of the UNOS registry.
    Hayes D; Higgins RS; Kirkby S; McCoy KS; Wehr AM; Lehman AM; Whitson BA
    J Cyst Fibros; 2014 Jul; 13(4):416-23. PubMed ID: 24388063
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cost-Effectiveness and Budget Impact of Lumacaftor/Ivacaftor in the Treatment of Cystic Fibrosis.
    Vadagam P; Kamal KM; Covvey JR; Giannetti V; Mukherjee K
    J Manag Care Spec Pharm; 2018 Oct; 24(10):987-997. PubMed ID: 30247102
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis physicians' perspectives on the timing of referral for lung transplant evaluation: a survey of physicians in the United States.
    Ramos KJ; Somayaji R; Lease ED; Goss CH; Aitken ML
    BMC Pulm Med; 2017 Jan; 17(1):21. PubMed ID: 28103851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Transplant center volume and outcomes in lung transplantation for cystic fibrosis.
    Hayes D; Sweet SC; Benden C; Kopp BT; Goldfarb SB; Visner GA; Mallory GB; Tobias JD; Tumin D
    Transpl Int; 2017 Apr; 30(4):371-377. PubMed ID: 28012223
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Chinese experts consensus statement: diagnosis and treatment of cystic fibrosis (2023)].
    ; ;
    Zhonghua Jie He He Hu Xi Za Zhi; 2023 Apr; 46(4):352-372. PubMed ID: 36990700
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of clinical response to ivacaftor with lung clearance index in cystic fibrosis patients with a G551D-CFTR mutation and preserved spirometry: a randomised controlled trial.
    Davies J; Sheridan H; Bell N; Cunningham S; Davis SD; Elborn JS; Milla CE; Starner TD; Weiner DJ; Lee PS; Ratjen F
    Lancet Respir Med; 2013 Oct; 1(8):630-638. PubMed ID: 24461666
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human epididymis protein 4 (HE4) levels inversely correlate with lung function improvement (delta FEV
    Nagy B; Bene Z; Fejes Z; Heltshe SL; Reid D; Ronan NJ; McCarthy Y; Smith D; Nagy A; Joseloff E; Balla G; Kappelmayer J; Macek M; Bell SC; Plant BJ; Amaral MD; Balogh I
    J Cyst Fibros; 2019 Mar; 18(2):271-277. PubMed ID: 30268371
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.